A genetic pioneer reveals what he learned from mapping his own genome.
Howard J. Jacob, Ph.D., vice president and head of genomic research, AbbVie
Howard J. Jacob, Ph.D., was a member of the first team ever to use genome sequencing to diagnose, treat and cure a patient. It was 2009, and the patient was a 6-year-old whose symptoms baffled doctors for years. Working with scientists and physicians, Dr. Jacob’s team sequenced the boy’s DNA and diagnosed his rare disease, which allowed him to undergo a successful bone marrow transplant.
Almost a decade later, Dr. Jacob is using the same technology to potentially help millions of patients. As AbbVie’s new vice president and head of genomic research, he brings decades of genomic knowledge from academia and the clinic into the company’s labs. We spoke with Dr. Jacob about the current state of whole genome sequencing, and its potential for both patients and those simply interested in learning more about their “own personal blueprint.”
Jacob: Whole genome sequencing (WGS) is the process of reading a person’s DNA. This is a massive amount of data -- three billion chemical units in the DNA from your mom and another three billion chemical units in your DNA from your dad. The genetic information derived is essentially a personal health blueprint revealing potential disease risks, how you will react to certain treatments and more. When scientists look at these blueprints for millions of people, ultimately we hope to make new and better medicines.
Jacob: I hope to help more patients, perhaps whole classes of patients. After decades in a clinical setting, I will miss directly working with patients. But in many ways, I bring these patients with me into the research labs here, where I work with a large team to use DNA sequencing to determine what causes some of the world’s most challenging diseases.
Jacob: Bridges are inspected using blueprints by structural engineers so they don’t fall down. What if doctors could use our personal blueprints the same way? Completing the mapping of the human genome in 2003 took more than a decade and one billion – and that was to map just one genome. Today, the same process takes a couple of days for a mere fraction of the cost. I would love to see a future where genomes are sequenced the day you are born so you know your risk of getting certain diseases, the best treatments to take and even which foods to eat to stay healthy.
Jacob: Of course! I would not let this technology pass me by. I discovered 50 common medicines that won’t work correctly for me based on my genetic makeup. I also modified my diet and reduced my chances of getting diabetes based on my results.
Jacob: In 20 years, I hope WGS is like the internet -- a technology that changed everything and is something we can’t imagine life without. Then, maybe we will be talking about curing and preventing diseases along with new treatments that are tailored to fit the makeup of individual patients.
Jacob: Science, exploration and forging new ground was my world even as a kid. When I was 5 years old, Jacques Cousteau was my hero; later in college, I switched my focus from marine biology to pharmacology, which was the focus of my Ph.D.
Jacob: Concepts for how we will use a million genomes to help discover new treatments. I want to use science and the latest cutting-edge technology available to help patients who need answers and new and better treatment options.
Media inquiries:
Jaquelin Finley
Email: [email protected]
Call: +1 847-937-4111
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?